1. Dynamics of Plasmodium species and genotype diversity in adults with asymptomatic infection in Gabon.
- Author
-
Inoue J, Galys A, Rodi M, Ekoka Mbassi D, Mombo-Ngoma G, Adegnika AA, Ramharter M, Zoleko-Manego R, Kremsner PG, Mordmüller B, and Held J
- Subjects
- Humans, Gabon epidemiology, Adult, Male, Female, Genetic Variation, Plasmodium falciparum genetics, Plasmodium falciparum drug effects, Plasmodium genetics, Plasmodium classification, Plasmodium isolation & purification, Plasmodium drug effects, Young Adult, Genotype, Asymptomatic Infections epidemiology, Malaria, Falciparum parasitology, Malaria, Falciparum epidemiology, Malaria, Falciparum drug therapy, Ivermectin therapeutic use
- Abstract
Objectives: We investigated the diversity and dynamics of Plasmodium infection in serially collected samples from asymptomatic participants of a clinical trial assessing the efficacy and safety of ivermectin in Gabon. We checked whether the baseline sample reflected the P. falciparum genotype and Plasmodium species diversity seen over 7 days of follow-up., Methods: Blood samples were collected at inclusion, every 8 hours until hour 72, daily until day 7, and on day 14. Plasmodium species was determined by qPCR and pfmsp1 length polymorphism was assessed for P. falciparum genotyping., Results: In 17/48 (35%) individuals, all pfmsp1 genotypes identified during the assessed period were detected at baseline; in 31/48 (65%), new genotypes were found during follow-up. Additional sampling at hour 24 allowed the identification of all genotypes seen over 7 days in 50% of the individuals. Ivermectin did not impact the genotype dynamics. Mixed Plasmodium spp. infections were detected in 28/49 (57%) individuals at baseline, and detection of non-falciparum infections during follow-up varied., Conclusions: Our results reveal complex intra-host dynamics of P. falciparum genotypes and Plasmodium species and underscore the importance of serial sampling in clinical trials for antimalarial drugs with asymptomatically P. falciparum-infected individuals. This might allow a more accurate identification of genotypes in multiple infections, impacting the assessment of drug efficacy., Competing Interests: Declarations of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF